Long-term maraviroc use as salvage therapy in HIV-2 infection

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2538-2539

  Caixas, Umbelina ^a,b   Ferreira, Joana ^a   Marinho, Aline T ^b   Faustino, Inês ^b   Grilo, Nádia M ^b   Lampreia, Fátima ^a   Germano, Isabel ^a   Monteiro, Emília C ^b   Pereira, Sofia A ^b  

^a Universidade de Lisboa   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

CCR5 antagonists; HIV 2 CCR5 tropism; Persistent low CD4 cell count; Second line HIV 2 therapy; Therapeutic drug monitoring

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; COTRIMOXAZOLE; DARUNAVIR PLUS RITONAVIR; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; RALTEGRAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VALGANCICLOVIR; VIRUS RNA; ZIDOVUDINE;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CASE REPORT; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENERAL CONDITION DETERIORATION; GENOTYPE; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LONG TERM CARE; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; SALVAGE THERAPY; STOP CODON; VIRAL TROPISM; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; DRUG MONITORING; HIV INFECTIONS; HIV-2; HUMANS; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 84866613168     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks240     Document Type: Letter

References (8)

1. Borrego P, Calado R, Marcelino JM et al. Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther 2012; 17: 565-70.
2. Visseaux B, Charpentier C, Hurtado-Nedelec M et al. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors. Antimicrob Agents Chemother 2012; 56: 137-9.
3. Stegmann S, Manea ME, Charpentier C et al. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J Clin Virol 2010; 47: 79-81.
4. Armstrong-James D, Stebbing J, Scourfield A et al. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res 2010; 86: 224-6.
5. Peterson K, Rowland-Jones S. Novel agents for the treatment of HIV-2 infection. Antivir Ther 2012; 17: 435-8.
6. Shi Y, Brandin E, Vincic E et al. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation. J Gen Virol 2005; 86: 3385-96.
7. Marcelino JM, Borrego P, Rocha C et al. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy. J Virol 2010; 84: 12429-36.
8. Soares R, Foxall R, Albuquerque A et al. Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type infection. J Virol 2006; 80: 12425-9.